ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

ClinicalTrials.gov ID: NCT04463771

Public ClinicalTrials.gov record NCT04463771. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 12:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)

Study identification

NCT ID
NCT04463771
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Incyte Corporation
Industry
Enrollment
206 participants

Conditions and interventions

Interventions

  • INCAGN02385 Drug
  • INCAGN02390 Drug
  • epacadostat Drug
  • pemigatinib Drug
  • retifanlimab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 25, 2021
Primary completion
Apr 13, 2026
Completion
Jul 9, 2026
Last update posted
Dec 9, 2025

2021 – 2026

United States locations

U.S. sites
29
U.S. states
19
U.S. cities
29
Facility City State ZIP Site status
Alaska Womens Cancer Care Akwcc Anchorage Alaska 99508
Honorhealth Phoenix Arizona 85016
Arizona Oncology Associates Tucson Arizona 85711
UCLA Medical Hematology & Oncology Los Angeles California 90048
Olive View Med Ctr Sylmar California 91342
Broward Health Medical Center Fort Lauderdale Florida 33316
Miami Cancer Institute Miami Florida 33176
Mount Sinai Medical Center Comprehensive Cancer Center Miami Beach Florida 33140
Advent Health Medical Group-Orlando 2501 Orlando Florida 32804
H. Lee Moffitt Cancer Center and Research Institute Hospital Tampa Florida 33612-9497
Georgia Cancer Center Augusta Georgia 30912
Barbara Ann Karmanos Cancer Hospital Detroit Michigan 48201
Minnesota Oncology-Maplewood Coon Rapids Minnesota 55433
Midwest Cancer Care Kansas City Missouri 64132
Washington University St Louis Missouri 63110
Billings Clinic Cancer Center Billings Montana 59101
Comprehensive Cancer Centers of Nevada Henderson Nevada 89074
New Mexico Cancer Care Alliance Albuquerque New Mexico 87131
Laura & Isaac Perlmutter Cancer Ctr New York New York 10016
University of North Carolina At Chapel Hill Chapel Hill North Carolina 27514
The Ohio State University Wexner Medical Center Division of Gynecologic Oncology Hilliard Ohio 43026
Willamette Valley Cancer Institute Eugene Oregon 97401-8122
Texas Oncology-Tyler Sioux Falls South Dakota 57104
Tennessee Oncology Nashville Tennessee 37203
Texas Oncology-Austin Center Austin Texas 78731
Texas Oncology-Fort Worth South Henderson Fort Worth Texas 76104-3902
Texas Oncology San Antonio San Antonio Texas 78240
Texas Oncology the Woodlands Shenandoah Texas 77380
Virginia Commonwealth University Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04463771, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 9, 2025 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04463771 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →